Spots Global Cancer Trial Database for First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
Official Title: An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation
Study ID: NCT01646450
Conditions
Interventions
Study Description
Brief Summary: A single arm, open label, phase IV trial to evaluate safety and efficacy of icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR.
Detailed Description: A single arm, open label, prospective, phase IV trial to evaluate safety and efficacy of icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR. * Primary endpoint to assess progression-free survival * Secondary endpoints to assess the overall survival, objective response rate, disease control rate and so on.
Keywords
Eligibility
Minimum Age: 70 Years
Eligible Ages: OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai Chest Hospital Affliated to Shanghai Jiaotong Univercity, Shanghai, Shanghai, China
Contact Details
Name: Han Baohui, MD
Affiliation: Shanghai Chest Hospital Affliated to Shanghai Jiaotong Univercity
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
